Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Lagevrio

Lagevrio
In stock
200mg
from A$359.23
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$431.08A$359.23
A$359.23 per bottle

In brief

  • Available from licensed pharmacies and hospital dispensaries; molnupiravir (Lagevrio) is prescription-only (Rx) in all authorised countries and not sold over the counter — while some pharmacies or online sellers may claim to supply without a receipt, doing so is not authorised and may be unsafe, so always follow local laws and prescriber guidance.
  • Lagevrio (molnupiravir) is an oral antiviral for early treatment of mild-to-moderate COVID‑19 in adults at increased risk of progression; it is a prodrug converted to a ribonucleoside analogue that is incorporated into viral RNA and induces viral error catastrophe (lethal mutagenesis), reducing viral replication.
  • Usual dose: 800 mg (four 200 mg capsules) twice daily for 5 days, started within 5 days of symptom onset.
  • Form of administration: oral 200 mg capsules (take by mouth); oral use only.
  • Onset time: antiviral activity begins after the first doses, but symptomatic improvement is not immediate — clinical benefits are usually assessed over 1–3 days and the regimen should be completed even if symptoms improve.
  • Duration of action: the prescribed treatment course is 5 days (do not extend beyond 5 days); the antiviral effect is intended for the duration of the course.
  • Alcohol warning: there is no specific formal alcohol interaction in product labelling, but avoid excess alcohol while unwell and during treatment as alcohol can worsen side effects (nausea, dizziness) and overall recovery.
  • The most common side effects are diarrhoea, nausea, headache and dizziness (diarrhoea is among the most frequently reported).
  • Would you like to try lagevrio without a prescription?

Critical Warnings & Restrictions

Basic Lagevrio Information

  • INN (International Nonproprietary Name): Molnupiravir.
  • Brand Names Available In Australia: Not specified.
  • ATC Code: J05AX66.
  • Forms & Dosages: 200 mg capsule; typical packaging 10–40 capsules; regimen 4 capsules twice daily for 5 days.
  • Manufacturers In Australia: Not specified.
  • Registration Status In Australia: Not specified.
  • OTC / Rx Classification: Prescription Only (Rx) in all referenced jurisdictions; not available over‑the‑counter.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

People planning pregnancy, pregnant people and breastfeeding people need specialist advice before any use of molnupiravir because animal data show potential embryotoxicity.

Use of molnupiravir is contraindicated in pregnancy and not authorised for people under 18 years of age.

Known hypersensitivity to molnupiravir or any capsule excipient is an absolute contraindication.

Patients hospitalised with severe or critical COVID‑19 should not receive molnupiravir as it is not authorised for severe disease.

Recommend pregnancy testing and documented contraception for people of child‑bearing potential before and during treatment according to product safety principles.

Discuss specialist referral for immunocompromised patients or those with severe hepatic or renal impairment, and for people with multiple complex comorbidities.

Prescribers should consider risk versus benefit and follow national guidance and updated product information.

  • Prescriber Checklist — Confirm: pregnancy test status; patient age; symptom onset date; known allergies; current medications; and written consent for emergency use or off‑label conditions (if applicable).

Interaction With Activities (Driving, Workplace Safety)

Dizziness and headache are among the known adverse effects and can affect fitness to drive or operate heavy machinery.

Advise patients not to drive or perform hazardous tasks if they experience dizziness, drowsiness or visual disturbance while taking molnupiravir.

Advise patients to avoid alcohol if feeling unwell, as alcohol may worsen dizziness or nausea.

Employers should be given temporary fitness‑for‑duty guidance: employees may need to avoid safety‑critical roles while symptomatic or experiencing adverse effects.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: If you experience dizziness, drowsiness or visual disturbance, do not drive.

If you tolerate the medication with no such effects, the usual driving laws apply.

Document counselling about driving and workplace safety in the patient record.

Usage Basics

INN, Brand Names And Local Packaging

The International Nonproprietary Name is molnupiravir and it is marketed internationally as Lagevrio™ by Merck/MSD and as generic brands such as Molnunat 200 mg in India.

Typical course packaging internationally is 200 mg capsules, usually 40 capsules per 5‑day treatment (four 200 mg capsules twice daily).

Brand Strength Typical Pack Course Size
Molnunat (India) 200 mg Blister strips, commonly 5–20 capsules 40 capsules (5 days)
Lagevrio™ (Merck / MSD) 200 mg Pack of 40 capsules (5‑day pack) 40 capsules (5 days)
Lagevrio™ (UK/Europe) 200 mg 5‑day packs of 40 capsules 40 capsules (5 days)

Legal Classification & Australian Regulatory Context

Molnupiravir is classified as prescription‑only (Rx) in all referenced jurisdictions and is not available over‑the‑counter.

Australian clinicians and pharmacists must verify current TGA ARTG registration and PBS status before prescribing or dispensing.

Emergency authorisations and access routes vary internationally and conditions of supply differ by country.

  • Actions For Australian Prescribers: Check the TGA ARTG entry for molnupiravir or Lagevrio.
  • Actions For Australian Prescribers: Confirm whether PBS listing applies to the patient and document indication and timing (start within 5 days of symptoms).
  • Actions For Australian Prescribers: Record informed consent when supply is via special access or emergency arrangements.

Dosing Guide

Standard Regimen (Evidence‑Based)

The standard adult dose is 800 mg (four 200 mg capsules) taken twice daily for five days.

Treatment should start as soon as possible and within five days of symptom onset for mild‑to‑moderate COVID‑19 in high‑risk adults.

The total duration is five days and should not be extended even if symptoms resolve early.

Dose Frequency Duration Start Window
800 mg (4 × 200 mg) Twice daily 5 days Begin within 5 days of symptom onset

Adjustments For Comorbidities

There are no formal dose adjustments stated for elderly patients in available product information.

Molnupiravir is not authorised for use in people under 18 years of age due to lack of safety and efficacy data.

Limited guidance exists for severe hepatic or renal impairment; consult specialist advice and the latest prescribing information for individual patients.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember unless it is close to the time for the next scheduled dose.

Do not double up doses to make up for a missed dose.

Continue the remainder of the prescribed regimen and contact the prescriber if more than one dose is missed.

  • Missed Dose Steps: Take as soon as remembered (unless near next dose).
  • When To Call Clinician: If two or more doses are missed or if vomiting occurs within an hour of dosing.
  • Adherence Importance: Completing the full five‑day course is recommended even if symptoms improve.

Interaction Chart (Food, Drink, Drugs)

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Available product information does not list major food interactions; molnupiravir may be taken with or without food to aid adherence.

Advise limiting heavy alcohol while unwell as alcohol can worsen dehydration and increase the chance of nausea or dizziness.

In Australia, advise patients to schedule twice‑daily doses around their normal meal times where practical, for example morning and evening meals or with morning and evening tea where appropriate.

  • Practical Tips: Take doses about 12 hours apart where possible to maintain steady timing.
  • Practical Tips: If nausea occurs, take with a small snack to improve tolerability.
  • Practical Tips: Keep well hydrated, particularly in hot Australian weather.

Common Drug Conflicts

Molnupiravir appears to have fewer cytochrome P450 interactions than ritonavir‑containing regimens such as nirmatrelvir/ritonavir.

Always review concomitant medicines with clinical decision support systems for newly identified interactions.

Advise dual contraception where product safety guidance requires contraception during and after treatment for people of child‑bearing potential.

Drug Class Interaction Risk Action
Hormonal Contraceptives Low (advise contraception guidance) Advise additional contraception as per product safety recommendations
Immunosuppressants Unknown / Limited Data Consult specialist; monitor closely
CYP450 Substrates Lower risk compared with ritonavir combos Review each agent; use clinical support tools

User Reports & Trends (Australian Patient Feedback)

Community feedback and pharmacy customer reports align with trial safety data: common complaints include diarrhoea, nausea, headache and dizziness.

Occasional reports mention rash or increased fatigue, but serious safety signals were not common in trials.

Remind patients that self‑reported experiences are useful but do not replace formal pharmacovigilance reports.

Pharmacies should collect local safety data using structured forms and follow up with patients at set intervals such as day 3 and day 14.

  • Top 5 Patient Comments: Diarrhoea; Nausea; Headache; Dizziness; Quick symptom relief (variable reports).
Symptom Frequency (Local Reports) Recommended Action
Diarrhoea Common Encourage hydration; advise antidiarrhoeal if needed and report if severe
Nausea Common Take with food; consider antiemetic if persistent
Headache / Dizziness Common Avoid driving if affected; symptomatic treatment

Report suspected adverse events to the Therapeutic Goods Administration (TGA) and local health units for serious events.

Access & Purchase Options (How Australians Obtain It)

National Chains & Community Pharmacies

Molnupiravir is available on prescription through licensed pharmacies and hospitals when authorised and stocked.

National pharmacy chains may dispense molnupiravir where supply and regulatory status permit.

  • Pharmacy Checklist: Verify prescription validity, batch and expiry, patient identification and counselling documentation prior to supply.

Online Pharmacies & Telehealth E‑Prescriptions

E‑prescriptions via telehealth are commonly used in Australia to obtain prescription medicines where permitted by law.

Transport does not require cold‑chain storage but keep packaging and temperature guidance during delivery.

Rural access may be improved by telehealth plus pharmacist delivery, although shortages and cost can limit availability.

Access Route Advantages Limitations (Urban Vs Rural)
Community Pharmacy Immediate counselling and supply May be limited by local stock
Online Pharmacy + Delivery Convenience and discrete delivery Delivery times and supply may be slower in rural areas
Hospital Supply Access for high‑risk or complex patients Requires hospital admission or specialist referral

In our online pharmacy, lagevrio is available without a prescription, with discreet delivery to Australia in 9‑21 days.

Note: product information indicates molnupiravir is prescription‑only; verify legality and supply routes before ordering.

Mechanism & Pharmacology

Simplified Explanation For Patients

Molnupiravir is an oral antiviral that acts as a ribonucleoside analogue and causes errors in the viral RNA during replication.

This leads to decreased production of viable SARS‑CoV‑2, a process sometimes described as “error catastrophe”.

The drug is classified under ATC code J05AX66 as an antiviral miscellaneous agent.

Clinical Terms For Prescribers

Molnupiravir is given orally as 200 mg capsules with a recommended dosing regimen of four capsules twice daily.

No alternative formulations are approved; only oral capsules are available as of July 2025.

Pharmacokinetic and dose adjustment data are limited for severe hepatic or renal impairment and specialist advice is recommended when in doubt.

  1. Ribonucleoside Analogue — A drug that mimics RNA building blocks and is incorporated into viral RNA.
  2. ATC Code — J05AX66, antiviral miscellaneous.
  3. EUA Vs MA — Emergency use authorisations differ from full marketing approval; check local regulatory status.

Indications & Off‑Label Uses

Approved Indications By Jurisdiction

Molnupiravir has been authorised under emergency or temporary authorisations in several countries for early treatment of mild‑to‑moderate COVID‑19 in high‑risk adults.

It is not authorised for prophylaxis or for hospitalised patients with severe disease.

Australian prescribers must check the current TGA authorisation and conditions before prescribing.

Off‑Label Uses In Practice (Warnings)

Off‑label uses such as pre‑ or post‑exposure prophylaxis, use in children under 18 or use in pregnancy are strongly discouraged due to lack of evidence or safety concerns.

  • Indication Appropriateness Checklist: Confirm authorised indication, document rationale, obtain informed consent if supply is exceptional.
Indication Authorised? Notes
Early Treatment Of Mild‑To‑Moderate COVID‑19 In High‑Risk Adults Yes (Emergency / Temporary Authorisations) Start within 5 days of symptom onset
Pre‑Exposure Or Post‑Exposure Prophylaxis No Not authorised
Children Under 18 No Not approved; safety not established

Key Clinical Findings (2022–2026 Overview)

Regulatory emergency use decisions were based on trials and early real‑world data showing a modest benefit in reducing progression to severe disease in certain high‑risk outpatients.

The safety profile in trials showed mainly mild to moderate adverse events such as diarrhoea, nausea, headache and dizziness.

Guideline positions and comparative efficacy estimates evolved between 2022 and 2026, so clinicians should consult the latest national guidance when choosing therapy.

  • Key Trial Themes: Modest reduction in hospitalisation for some high‑risk groups; timing of start is critical.
  • Limitations: Variable efficacy by variant and patient risk profile; fewer interactions than ritonavir combos but lower efficacy in some analyses.
  • Safety Signals: Mostly mild–moderate adverse events; embryotoxicity concerns from animal data require pregnancy avoidance.
Study Population Primary Outcome Caveats
Key Trial A High‑risk outpatients Hospitalisation or death reduction Modest benefit; timing within 5 days important
Real‑World Cohorts Community high‑risk adults Variable effectiveness Confounding factors; evolving variants

Compare results with alternatives such as nirmatrelvir/ritonavir (Paxlovid) when weighing options for each patient.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Agent Route Indication Major Interactions PBS Status
Paxlovid (nirmatrelvir/ritonavir) Oral Early treatment of high‑risk adults Many CYP3A interactions (ritonavir) Varies by jurisdiction (check PBS)
Remdesivir (Veklury®) IV Hospitalised patients Renal and hepatic monitoring advised Varies; hospital use
Sotrovimab (Xevudy®) IV Outpatient monoclonal antibody (availability varies) Minimal drug interactions Availability varies

Pros & Cons Checklist

  • Pros For Molnupiravir: Oral route, relatively simple regimen and fewer known drug interactions than ritonavir‑containing options.
  • Cons For Molnupiravir: Contraindicated in pregnancy, lower efficacy in some analyses, not for severe disease.
  • Decision Support Checklist: Assess patient risk factors, drug interactions, pregnancy and breastfeeding status, supply and cost.

Common Questions (Pharmacy Consultations)

“Am I Eligible?” — Eligibility depends on local regulatory authorisation and whether the patient meets high‑risk criteria; start within five days of symptom onset.

“When Must It Be Started?” — As soon as possible and within five days of symptom onset for maximum potential benefit.

“Is It On The PBS?” — Check current PBS listings before counselling; PBS status may change and varies by indication.

“Is It Safe In Pregnancy/Breastfeeding?” — Contraindicated in pregnancy; breastfeeding use is not recommended without specialist advice.

“Can I Take Other Meds?” — Review the full medication list and consult clinical decision support for interactions; fewer interactions than ritonavir combos but specialist review may be needed.

  • Top 10 Phrases For Counselling: Confirm identity; explain purpose; show dosing; state start window; state contraindications; name common side effects; give driving advice; advise contraception; outline when to seek urgent care; offer follow‑up.

Place a laminated quick‑reference card behind the counter with contraindications, dosing, start window and adverse‑event red flags for staff use.

Price & Access Comparison Table (Practical)

Suggested Comparison Table Fields

Do not publish fixed prices without current verification; include fields for pharmacy/source, typical private price range (AUD), PBS subsidy status, prescription required, delivery options and rural availability.

Pharmacy/Source Typical Private Price Range (AUD) PBS Subsidy Prescription Required Delivery Options Rural Availability
Community Pharmacy Verify Current Market Price Check PBS Yes In‑store or local delivery Variable
Online Pharmacy Verify Current Market Price Check PBS Yes Nationwide delivery Delivery times may be longer

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Confirm TGA and PBS status before supply.
  • Check telehealth and e‑prescription acceptability for the pharmacy.
  • Check pharmacy stocklist and batch expiry prior to dispensing.
  • Consider patient concession cards and out‑of‑pocket counselling for costs.

Registration & Regulation (TGA, PBS Practical Steps)

TGA Approval — How To Verify

Search the TGA ARTG database for “molnupiravir” or “Lagevrio” and review any conditions of authorisation or provisional approval.

If molnupiravir is not on the ARTG, access may require special access schemes or hospital supply lines.

PBS Subsidy Details & Prescriber Responsibilities

If PBS listing exists, verify eligibility criteria and authority prescription conditions before issuing a PBS script.

If not subsidised, counsel patients on private prescription costs and document informed consent for supply.

  • Regulatory Checklist: ARTG check; PBS Schedule search; maintain recordkeeping for supply and counselling.

Report adverse events to the TGA and use the available regulatory contact routes for urgent queries.

Storage & Handling (Household & Pharmacy)

Household Storage In Australian Climate

Store molnupiravir at 20–25°C with permitted excursions to 15–30°C.

Protect capsules from moisture and keep in the original packaging until use.

Do not freeze and avoid prolonged exposure to direct sunlight.

Advise patients in hot and humid Australian summers to store medication in a cool, dry place out of reach of children.

Cold‑Chain & Pharmacy Handling

No refrigerated storage is required, but pharmacies should monitor ambient storage conditions and transport to patients in appropriate packaging.

Maintain temperature logs where pharmacy procedures require them and verify batch and expiry before dispensing.

  • Dispensing Checklist: Verify packaging integrity, expiry date, provide storage counselling and advise safe disposal of unused capsules.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

Australian Pharmacist Counselling Style

Confirm patient identity and the indication for which the medicine has been prescribed or supplied.

Check the date of symptom onset and confirm treatment will start within five days.

Explain dosing: four 200 mg capsules twice daily for five days and emphasise completing the full course.

Review absolute contraindications including pregnancy and age under 18, and discuss contraception requirements for people of child‑bearing potential.

Describe common side effects (diarrhoea, nausea, headache, dizziness) and advise when to seek urgent care for worsening breathlessness, chest pain or severe rash.

  • Before Supply: Confirm prescription, allergies, pregnancy status and current meds.
  • At Supply: Provide dosing schedule, storage advice and side‑effect counselling.
  • Follow‑Up: Offer phone follow‑up on day 3 and day 14 to check tolerability and outcomes.

Patient Advice From PBS And National Health Authorities

Reinforce that molnupiravir is not a substitute for COVID‑19 vaccination and is not authorised for prophylaxis.

Discuss contraception during and after treatment as per product safety guidance and advise reporting any adverse events.

Offer a printed patient information sheet with clear contact numbers and escalation pathways.

Delivery Across Australia

City Region Delivery time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Canberra Australian Capital Territory 9–14 days
Gold Coast Queensland 9–14 days
Newcastle New South Wales 9–14 days
Wollongong New South Wales 9–14 days
Geelong Victoria 9–14 days
Hobart Tasmania 14–21 days
Darwin Northern Territory 14–21 days
Cairns Queensland 14–21 days
Townsville Queensland 14–21 days

Related products